Difference between revisions of "Voxelotor (Oxbryta)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== hemoglobin S polymerization inhibitor ==Diseases for which it is used== *Sickle cell anemia ==History of changes in FDA indication== *11/25/2019:...") |
m |
||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/25/2019: Granted accelerated approval for the treatment of [[Sickle cell anemia|sickle cell disease]] in adults and pediatric patients 12 years of age and older. | *11/25/2019: Granted accelerated approval for the treatment of [[Sickle cell anemia|sickle cell disease]] in adults and pediatric patients 12 years of age and older. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' GBT-440, GTx-011 | ||
| + | *'''Brand name:''' Oxbryta | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 21:33, 2 April 2021
Mechanism of action
hemoglobin S polymerization inhibitor
Diseases for which it is used
History of changes in FDA indication
- 11/25/2019: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
Also known as
- Code names: GBT-440, GTx-011
- Brand name: Oxbryta